Kala Bio (LTS:0JQ2) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kala Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kala Bio's Free Cash Flow for the three months ended in Sep. 2024 was $-4.82 Mil. Kala Bio's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Kala Bio's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Kala Bio's current FCF Yield % is -108.81%.

The historical rank and industry rank for Kala Bio's FCF Margin % or its related term are showing as below:

During the past 9 years, the highest FCF Margin % of Kala Bio was -1012.22%. The lowest was -34091.11%. And the median was -1548.49%.

LTS:0JQ2's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Kala Bio FCF Margin % Historical Data

The historical data trend for Kala Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio FCF Margin % Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,548.49

-1,456.08

-1,012.22

-2,035.48

Kala Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kala Bio's FCF Margin %

For the Biotechnology subindustry, Kala Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kala Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kala Bio's FCF Margin % falls into.

Kala Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kala Bio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-28.537	/	0
	=	%

Kala Bio's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-4.815	/	0
	=	%

Kala Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kala Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KALA:USA 27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio Headlines

No Headlines